Trial · NCT01285037
A Study of LY2801653 in Advanced Cancer
NCT01285037, Phase 1, Completed, Eli Lilly and Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of LY2801653 in Advanced Cancer. Trials, record NCT01285037. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01285037
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of LY2801653 in Advanced Cancer
- NCT number
- NCT01285037
- Status
- Completed
- Phases
- Phase 1
- Enrollment
- 190 participants, actual
- Lead sponsor
- Eli Lilly and Company
- Conditions
- Cancer
- Interventions
- LY2801653, Cetuximab, Cisplatin, Gemcitabine, Ramucirumab
- First posted
- 2011-01-27
- Last updated
- 2018-02-20
Source ClinicalTrials.gov
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Recommended dose for phase 2 studies: Maximum tolerated dose | Baseline to study completion (estimated as 3 months) | |
| Secondary | Number of participants with tumor response | Part A: Baseline to study completion (estimated as 3 months) | |
| Secondary | Clinical benefit rate (CBR) | Parts B, C, D: Baseline to study completion (estimated as 3 months) | |
| Secondary | Progression free survival (PFS) | Parts B, C, D: Baseline to study completion (estimated as up to 6 months) | |
| Secondary | Duration of response | Parts B, C, D: Baseline to study completion (estimated as up to 6 months) | |
| Secondary | Number of participants with clinically significant effects | Baseline to study completion (estimated as 3 months) | |
| Secondary | Pharmacokinetics: Area under the concentration/time curve (AUC) | Cycle 1, Day 1; Cycle 2, Day 1 | |
| Secondary | Pharmacokinetics: Maximum plasma concentration (Cmax) | Cycle 1, Day 1; Cycle 2, Day 1 | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with cetuximab for phase 2 studies in HNSCC | Baseline to study completion (estimated as 3 months) | |
| Secondary | Maximum tolerated dose (MTD) of LY2801653 in combination with cisplatin for phase 2 studies in cholangiocarcinoma | Baseline to study completion (estimated as 3 months) |
1 to 10 of 12Source ClinicalTrials.gov
See all 12 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01285037
GET https://conductscience.org/api/trials/v1/NCT01285037/registered